Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Aflibercept Humanized Recombinant Human Monoclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
MA5-42317
产品规格
种属反应
Human
宿主/亚型
Human
/ IgG1, Fc
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
抗原
Human VEGFA
偶联物
形式
Liquid
浓度
2.37 mg/mL
纯化类型
Protein A/G
保存液
PBS, pH 7.4
内含物
no preservative
保存条件
-20°C, Avoid Freeze/Thaw Cycles
运输条件
Ambient (domestic); Wet ice (international)
RRID
产品详细信息
Endotoxin level < 0.01EU/µg by LAL method
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
靶标信息
Biosimilars targeting aflibercept biosimilars such as Yesafili, Opuviz, and Pavblu, function by inhibiting vascular endothelial growth factor (VEGF) pathways, crucial for angiogenesis and vascular permeability. These biosimilars emulate the activity of aflibercept, a recombinant fusion protein that combines portions of VEGF receptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2) with an immunoglobulin G (IgG) Fc fragment, effectively acting as a decoy receptor for VEGF-A, VEGF-B, and placental growth factor (PlGF). By binding to these growth factors, the biosimilars prevent their interaction with VEGF receptors on the surface of endothelial cells, thereby inhibiting the pathological angiogenesis and increased vascular permeability seen in conditions like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Clinical studies have shown that biosimilars such as SCD411, SB15, and QL1207 demonstrate comparable efficacy and safety to the reference product, aflibercept, in these indications, offering alternative treatment options that meet rigorous equivalency standards set by regulatory bodies.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
